Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis

• Auteurs principaux: Xue-Yan Zhang (Auteur), Bo-Chi Zhu (Auteur), Miao He (Auteur), Shan-Shan Dong (Auteur)
• Format: Livre
• Publié: BMC, 2024-05-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract Ovarian cancer is a major gynecological cancer that has poor prognosis associated mainly to its late diagnosis. Cisplatin is an FDA approved ovarian cancer therapy and even though the therapy is initially promising, the patients mostly progress to resistance against cisplatin. The underlyin...